Pravin U. Dugel M.D.
Net Worth

Last updated:

What is Pravin U. Dugel M.D. net worth?

The estimated net worth of Dr. Pravin U. Dugel M.D. is at least $3,302,028 as of 3 May 2023. He has earned $179,428 from insider trading and has received compensation worth at least $3,122,600 in IVERIC bio, Inc..

What is the salary of Pravin U. Dugel M.D.?

Dr. Pravin U. Dugel M.D. salary is $780,650 per year as Pres in IVERIC bio, Inc..

How old is Pravin U. Dugel M.D.?

Dr. Pravin U. Dugel M.D. is 61 years old, born in 1964.

What stocks does Pravin U. Dugel M.D. currently own?

As insider, Dr. Pravin U. Dugel M.D. owns shares in one company:

Company Title Shares Price per share Total value
IVERIC bio, Inc. (ISEE) Pres 41,699 $0 $0

What does IVERIC bio, Inc. do?

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

ISEE logo
ISEE
IVERIC bio, Inc.

Pravin U. Dugel M.D. insider trading

IVERIC bio, Inc.

Dr. Pravin U. Dugel M.D. has made only one insider trade between 2021-2023, according to the Form 4 filled with the SEC.

As of 3 May 2023 he still owns at least 41,699 units of ISEE stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 4,312 N/A N/A
Option
Restricted Stock Units 4,312 N/A N/A
Option
Common Stock 50,000 N/A N/A
Option
Restricted Stock Units 50,000 N/A N/A
Option
Common Stock 12,500 N/A N/A
Option
Restricted Stock Units 12,500 N/A N/A
Option
Common Stock 13,750 N/A N/A
Option
Restricted Stock Units 13,750 N/A N/A
Option
Common Stock 8,474 $10.03 $84,994
Option
Stock Option (right to buy) 8,474 $10.03 $84,994
Option
Common Stock 4,313 N/A N/A
Option
Restricted Stock Units 4,313 N/A N/A
Option
Common Stock 50,000 N/A N/A
Option
Restricted Stock Units 50,000 N/A N/A
Option
Restricted Stock Units 13,750 N/A N/A
Option
Common Stock 13,750 N/A N/A
Option
Stock Option (Right to Buy) 4,237 $1.65 $7,000
Option
Common Stock 4,237 $1.65 $7,000
Sale
Common Stock 28,301 $6.34 $179,428
Option
Common Stock 70,000 N/A N/A
Option
Common Stock 70,000 N/A N/A
Option
Restricted Stock Units 70,000 N/A N/A

IVERIC bio key executives

IVERIC bio, Inc. executives and other stock owners filed with the SEC:

  • Dr. Pravin U. Dugel M.D. (61) Pres
  • Mr. David F. Carroll (59) Senior Vice President, Chief Financial Officer & Treasurer
  • Mr. Glenn P. Sblendorio M.B.A. (69) Chief Executive Officer & Director
  • Mr. Keith Westby M.B.A. (50) Senior Vice President & Chief Operating Officer